LeonaBio, Inc.

LONA · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
93
SEC Filings

Business Summary

. Overview We are a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patients lives. Following a review of potential therapeutic and business opportunities, we acquired rights to a promising late-stage asset, lasofoxifene, for the potential treatment of ESR1-mutated (mESR1) metastatic breast cancer in D...

Next Earnings

Q2 FY2026 — expected 2026-09-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionLONAdiscussed_in_filing Cybersecurity
topic_mentionLONAdiscussed_in_filing Cybersecurity
topic_mentionLONAdiscussed_in_filing Healthcare & Bio
topic_mentionLONAdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001193125-26-134565EDGAR117K words
2025-02-272024-12-310000950170-25-029069EDGAR—
2024-02-222023-12-310000950170-24-018787EDGAR—
2023-03-232022-12-310000950170-23-009498EDGAR—
2022-03-282021-12-310000950170-22-004782EDGAR—
2021-03-252020-12-310001564590-21-015495EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-269544EDGAR67K words
2025-08-072025-06-300000950170-25-105052EDGAR—
2025-05-092025-03-310000950170-25-068040EDGAR—
2024-11-072024-09-300000950170-24-123372EDGAR—
2024-08-012024-06-300000950170-24-089304EDGAR—
2024-05-152024-03-310000950170-24-060482EDGAR—
2023-11-092023-09-300000950170-23-062082EDGAR—
2023-08-102023-06-300000950170-23-041346EDGAR—
2023-05-112023-03-310000950170-23-021274EDGAR—
2022-11-102022-09-300000950170-22-024499EDGAR—
2022-08-152022-06-300000950170-22-017421EDGAR—
2022-05-122022-03-310000950170-22-009683EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-260001193125-26-126579EDGAR3K words
2026-03-190001193125-26-116123EDGAR—
2026-01-090001193125-26-008904EDGAR—
2025-12-180001193125-25-323692EDGAR—
2025-11-060001193125-25-269506EDGAR—
2025-10-030001193125-25-229293EDGAR—
2025-09-110000950170-25-114093EDGAR—
2025-08-070000950170-25-105029EDGAR—
2025-06-020000950170-25-080234EDGAR—
2025-05-090000950170-25-068020EDGAR—

93 total filings indexed. 65 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001620463
TickerLONA
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 758bf9bb0a723efb4ab3406b50a9c729caf5916a079bcf4d4bac7b5a4cc35f93
parent: bf8b7600596aef6b424c13e9eea66590ce0b49b3cdc141066e527ee3000e9041
content hash: c38ff2a954e08cfdad09a594cef784ed66498331128502a4c77af941451f97d3
signed: 2026-04-13T04:46:05.046Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf